Progression of Bruton tyrosine kinase (BTK) inhibitor in B-cell lymphoma
10.3969/j.issn.1000-8179.2016.14.476
- VernacularTitle:布鲁顿酪氨酸激酶抑制剂在B细胞淋巴瘤中的研究进展
- Author:
Jiao LI
;
Ning DING
;
Jun ZHU
;
Yuqin SONG
- Publication Type:Journal Article
- Keywords:
BTK inhibitor;
B-cell lymphoma;
BCR signaling
- From:
Chinese Journal of Clinical Oncology
2016;43(14):598-602
- CountryChina
- Language:Chinese
-
Abstract:
Chronic activation of the B-cell antigen receptor (BCR) signaling pathway performs a critical function in the pathogenesis of numerous subtypes of B-cell malignancies and transforms normal cells into malignant cells. Bruton tyrosine kinase (BTK) is a member of the TEC family of tyrosine kinases and is a key regulator of the BCR signaling pathway. BTK inhibition has emerged as a new target for therapeutic intervention in B-cell malignancies. This review summarizes recent developments of BTK inhibitors in B-cell malignan-cies.
